Hemogenyx Pharmaceuticals (HEMO)

Sector:

Pharma and Biotech

1.25p
   
  • Change Today:
      0.001p
  • 52 Week High: 2.05
  • 52 Week Low: 1.10
  • Currency: UK Pounds
  • Shares Issued: 979.75m
  • Volume: 1,169,657
  • Market Cap: £12.29m
  • RiskGrade: 340

HEMO Overview

Hemogenyx Pharmaceuticals Plc is a biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces the readmission of its enlarged issued share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange. The Company is the holding company for Hemogenyx LLC, a US-based biotechnology company developing therapies to transform bone marrow and blood stem cell transplantation. These therapies will replace the need for existing methods of preparation of patients for a transplantation such as chemotherapy and radiation treatments, and will address the problem of finding a matching stem cell donor and reduce the risk of blood stem cell rejection after transplantation.
Competitors: Okyo Pharma Limited , Nuformix

Key Personnel

CEO: Vladislav Sandler Ph.D.
Non-Executive Chairman: Marc Feldmann
Non-Executive Dir: Peter Redmond, Alexis M. Sandler

Contact Details

Address: 6th Floor, 60 Gracechurch Street, London, United Kingdom, EC3V 0HR
Website: http://hemogenyx.com/

Listings

Sector: Pharma and Biotech(LSE)
Overseas Listings: BATSLON:SILFL
ISIN: GB00BYX3WZ24

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HEMO Market Data

Currency UK Pounds
Share Price 1.25p
Change Today 0.001p
% Change -0.08 %
52 Week High 2.05
52 Week Low 1.10
Volume 1,169,657
Shares Issued 979.75m
Market Cap £12.29m
RiskGrade 340

HEMO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
3.28% above the market average3.28% above the market average3.28% above the market average3.28% above the market average3.28% above the market average
29.82% above the sector average29.82% above the sector average29.82% above the sector average29.82% above the sector average29.82% above the sector average
Price Trend
62.43% below the market average62.43% below the market average62.43% below the market average62.43% below the market average62.43% below the market average
23.81% below the sector average23.81% below the sector average23.81% below the sector average23.81% below the sector average23.81% below the sector average
Income Not Available
Growth Not Available

HEMO Dividends

No dividends found

Trades for 01-Dec-2022

Time Volume / Share Price
12:52 32,553 @ 1.25p
11:43 976 @ 1.25p
11:33 13,738 @ 1.25p
11:02 23,823 @ 1.25p
10:33 5,000 @ 1.25p

HEMO Key Personnel

CEO Vladislav Sandler Ph.D.

Top of Page